#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=Genome-wide DNA methylation patterns and methylation abnormalities in pituitary tumors have been reported previously .
2-1	14-25	Genome-wide	abstract[4]	new[4]	_	_
2-2	26-29	DNA	abstract|abstract[4]	new|new[4]	coref	4-22
2-3	30-41	methylation	abstract|abstract[4]	new|new[4]	coref	2-6
2-4	42-50	patterns	abstract[4]	new[4]	_	_
2-5	51-54	and	_	_	_	_
2-6	55-66	methylation	abstract|abstract[6]	giv|new[6]	coref	3-9[11_0]
2-7	67-80	abnormalities	abstract[6]	new[6]	_	_
2-8	81-83	in	abstract[6]	new[6]	_	_
2-9	84-93	pituitary	abstract[6]|object[7]	new[6]|new[7]	coref	4-32[28_7]
2-10	94-100	tumors	abstract[6]|object[7]	new[6]|new[7]	_	_
2-11	101-105	have	_	_	_	_
2-12	106-110	been	_	_	_	_
2-13	111-119	reported	_	_	_	_
2-14	120-130	previously	_	_	_	_
2-15	131-132	.	_	_	_	_

#Text=To date , however , the impact of aberrant CpG methylation on gene expression in NFPAs has not been investigated by a multi-omics approach .
3-1	133-135	To	_	_	_	_
3-2	136-140	date	time	new	_	_
3-3	141-142	,	_	_	_	_
3-4	143-150	however	_	_	_	_
3-5	151-152	,	_	_	_	_
3-6	153-156	the	abstract[9]	new[9]	_	_
3-7	157-163	impact	abstract[9]	new[9]	_	_
3-8	164-166	of	abstract[9]	new[9]	_	_
3-9	167-175	aberrant	abstract[9]|abstract[11]	new[9]|giv[11]	coref	4-22[26_11]
3-10	176-179	CpG	abstract[9]|abstract|abstract[11]	new[9]|new|giv[11]	coref	10-2
3-11	180-191	methylation	abstract[9]|abstract[11]	new[9]|giv[11]	_	_
3-12	192-194	on	abstract[9]	new[9]	_	_
3-13	195-199	gene	abstract[9]|abstract|abstract[13]	new[9]|new|new[13]	coref|coref	4-37[0_13]|9-9
3-14	200-210	expression	abstract[9]|abstract[13]	new[9]|new[13]	_	_
3-15	211-213	in	abstract[9]	new[9]	_	_
3-16	214-219	NFPAs	abstract[9]|abstract	new[9]|new	coref	5-1[33_0]
3-17	220-223	has	_	_	_	_
3-18	224-227	not	_	_	_	_
3-19	228-232	been	_	_	_	_
3-20	233-245	investigated	_	_	_	_
3-21	246-248	by	_	_	_	_
3-22	249-250	a	abstract[15]	new[15]	_	_
3-23	251-262	multi-omics	abstract[15]	new[15]	_	_
3-24	263-271	approach	abstract[15]	new[15]	_	_
3-25	272-273	.	_	_	_	_

#Text=In this study , we combined the results of methylome and transcriptome profiling of 33 gonadotroph NFPA samples to investigate whether DNA methylation at particular CpGs that are aberrantly methylated in gonadotroph tumors correlates with the expression levels of the corresponding genes .
4-1	274-276	In	_	_	_	_
4-2	277-281	this	abstract[16]	new[16]	coref	21-2[186_16]
4-3	282-287	study	abstract[16]	new[16]	_	_
4-4	288-289	,	_	_	_	_
4-5	290-292	we	person	acc	ana	6-2
4-6	293-301	combined	_	_	_	_
4-7	302-305	the	abstract[18]	new[18]	coref	14-1[122_18]
4-8	306-313	results	abstract[18]	new[18]	_	_
4-9	314-316	of	abstract[18]	new[18]	_	_
4-10	317-326	methylome	abstract[18]|substance|abstract[21]	new[18]|new|new[21]	_	_
4-11	327-330	and	abstract[18]|abstract[21]	new[18]|new[21]	_	_
4-12	331-344	transcriptome	abstract[18]|substance|abstract[21]	new[18]|new|new[21]	_	_
4-13	345-354	profiling	abstract[18]|abstract[21]	new[18]|new[21]	_	_
4-14	355-357	of	abstract[18]|abstract[21]	new[18]|new[21]	_	_
4-15	358-360	33	abstract[18]|abstract[21]|object[24]	new[18]|new[21]|new[24]	_	_
4-16	361-372	gonadotroph	abstract[18]|abstract[21]|animal|object[24]	new[18]|new[21]|new|new[24]	coref	5-1
4-17	373-377	NFPA	abstract[18]|abstract[21]|substance|object[24]	new[18]|new[21]|new|new[24]	_	_
4-18	378-385	samples	abstract[18]|abstract[21]|object[24]	new[18]|new[21]|new[24]	_	_
4-19	386-388	to	_	_	_	_
4-20	389-400	investigate	_	_	_	_
4-21	401-408	whether	_	_	_	_
4-22	409-412	DNA	abstract|abstract[26]	giv|giv[26]	coref|coref	5-7|5-7[36_26]
4-23	413-424	methylation	abstract[26]	giv[26]	_	_
4-24	425-427	at	abstract[26]	giv[26]	_	_
4-25	428-438	particular	abstract[26]|abstract[27]	giv[26]|new[27]	coref	5-20[39_27]
4-26	439-443	CpGs	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-27	444-448	that	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-28	449-452	are	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-29	453-463	aberrantly	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-30	464-474	methylated	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-31	475-477	in	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
4-32	478-489	gonadotroph	abstract[26]|abstract[27]|object[28]	giv[26]|new[27]|giv[28]	coref	6-25[0_28]
4-33	490-496	tumors	abstract[26]|abstract[27]|object[28]	giv[26]|new[27]|giv[28]	_	_
4-34	497-507	correlates	_	_	_	_
4-35	508-512	with	_	_	_	_
4-36	513-516	the	abstract[30]	new[30]	_	_
4-37	517-527	expression	abstract|abstract[30]	giv|new[30]	coref	7-27[55_0]
4-38	528-534	levels	abstract[30]	new[30]	_	_
4-39	535-537	of	abstract[30]	new[30]	_	_
4-40	538-541	the	abstract[30]|abstract[31]	new[30]|new[31]	coref	6-19[45_31]
4-41	542-555	corresponding	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-42	556-561	genes	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-43	562-563	.	_	_	_	_

#Text=Gonadotroph NFPAs exhibited an increase in DNA methylation relative to normal pituitary sections , and a large number of differentially methylated CpGs have been identified .
5-1	564-575	Gonadotroph	animal|abstract[33]	giv|giv[33]	coref|coref	6-15[0_33]|7-18
5-2	576-581	NFPAs	abstract[33]	giv[33]	_	_
5-3	582-591	exhibited	_	_	_	_
5-4	592-594	an	abstract[34]	new[34]	coref	13-31[119_34]
5-5	595-603	increase	abstract[34]	new[34]	_	_
5-6	604-606	in	abstract[34]	new[34]	_	_
5-7	607-610	DNA	abstract[34]|abstract|abstract[36]	new[34]|giv|giv[36]	coref|coref	7-6[49_36]|9-6
5-8	611-622	methylation	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
5-9	623-631	relative	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
5-10	632-634	to	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
5-11	635-641	normal	abstract[34]|abstract[36]|object[37]	new[34]|giv[36]|new[37]	coref	7-21[54_37]
5-12	642-651	pituitary	abstract[34]|abstract[36]|object[37]	new[34]|giv[36]|new[37]	_	_
5-13	652-660	sections	abstract[34]|abstract[36]|object[37]	new[34]|giv[36]|new[37]	_	_
5-14	661-662	,	_	_	_	_
5-15	663-666	and	_	_	_	_
5-16	667-668	a	abstract[38]	new[38]	_	_
5-17	669-674	large	abstract[38]	new[38]	_	_
5-18	675-681	number	abstract[38]	new[38]	_	_
5-19	682-684	of	abstract[38]	new[38]	_	_
5-20	685-699	differentially	abstract[38]|abstract[39]	new[38]|giv[39]	coref	6-9[43_39]
5-21	700-710	methylated	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
5-22	711-715	CpGs	abstract[38]|abstract[39]	new[38]|giv[39]	_	_
5-23	716-720	have	_	_	_	_
5-24	721-725	been	_	_	_	_
5-25	726-736	identified	_	_	_	_
5-26	737-738	.	_	_	_	_

#Text=In our analysis , approximately 85 % of CpGs that are differentially methylated in NFPAs and associated with known human genes were hypermethylated in tumors .
6-1	739-741	In	_	_	_	_
6-2	742-745	our	person|abstract[41]	giv|new[41]	ana|coref	7-1|7-1[48_41]
6-3	746-754	analysis	abstract[41]	new[41]	_	_
6-4	755-756	,	_	_	_	_
6-5	757-770	approximately	abstract[42]	new[42]	_	_
6-6	771-773	85	abstract[42]	new[42]	_	_
6-7	774-775	%	abstract[42]	new[42]	_	_
6-8	776-778	of	abstract[42]	new[42]	_	_
6-9	779-783	CpGs	abstract[42]|abstract[43]	new[42]|giv[43]	coref	7-12[51_43]
6-10	784-788	that	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-11	789-792	are	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-12	793-807	differentially	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-13	808-818	methylated	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-14	819-821	in	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-15	822-827	NFPAs	abstract[42]|abstract[43]|abstract	new[42]|giv[43]|giv	coref	21-11
6-16	828-831	and	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-17	832-842	associated	abstract[42]|abstract[43]	new[42]|giv[43]	_	_
6-18	843-847	with	_	_	_	_
6-19	848-853	known	abstract[45]	giv[45]	coref	7-30[56_45]
6-20	854-859	human	abstract[45]	giv[45]	_	_
6-21	860-865	genes	abstract[45]	giv[45]	_	_
6-22	866-870	were	_	_	_	_
6-23	871-886	hypermethylated	_	_	_	_
6-24	887-889	in	_	_	_	_
6-25	890-896	tumors	object	giv	coref	10-45[85_0]
6-26	897-898	.	_	_	_	_

#Text=Our correlation-based analysis revealed that methylation of a major fraction of CpGs that are differentially methylated in gonadotroph adenomas and pituitary sections did not correlate with the expression of the annotated genes .
7-1	899-902	Our	person|abstract[48]	giv|giv[48]	coref|ana	8-7[58_48]|9-1
7-2	903-920	correlation-based	abstract[48]	giv[48]	_	_
7-3	921-929	analysis	abstract[48]	giv[48]	_	_
7-4	930-938	revealed	_	_	_	_
7-5	939-943	that	_	_	_	_
7-6	944-955	methylation	abstract[49]	giv[49]	coref	9-6[63_49]
7-7	956-958	of	abstract[49]	giv[49]	_	_
7-8	959-960	a	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-9	961-966	major	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-10	967-975	fraction	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-11	976-978	of	abstract[49]|abstract[50]	giv[49]|new[50]	_	_
7-12	979-983	CpGs	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	coref	9-16[68_51]
7-13	984-988	that	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-14	989-992	are	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-15	993-1007	differentially	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-16	1008-1018	methylated	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-17	1019-1021	in	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-18	1022-1033	gonadotroph	abstract[49]|abstract[50]|abstract[51]|animal|animal[53]	giv[49]|new[50]|giv[51]|giv|new[53]	coref|coref	10-22[78_53]|27-9
7-19	1034-1042	adenomas	abstract[49]|abstract[50]|abstract[51]|animal[53]	giv[49]|new[50]|giv[51]|new[53]	_	_
7-20	1043-1046	and	abstract[49]|abstract[50]|abstract[51]	giv[49]|new[50]|giv[51]	_	_
7-21	1047-1056	pituitary	abstract[49]|abstract[50]|abstract[51]|object[54]	giv[49]|new[50]|giv[51]|giv[54]	coref	21-13[193_54]
7-22	1057-1065	sections	abstract[49]|abstract[50]|abstract[51]|object[54]	giv[49]|new[50]|giv[51]|giv[54]	_	_
7-23	1066-1069	did	_	_	_	_
7-24	1070-1073	not	_	_	_	_
7-25	1074-1083	correlate	_	_	_	_
7-26	1084-1088	with	_	_	_	_
7-27	1089-1092	the	abstract[55]	giv[55]	ana	8-1[0_55]
7-28	1093-1103	expression	abstract[55]	giv[55]	_	_
7-29	1104-1106	of	abstract[55]	giv[55]	_	_
7-30	1107-1110	the	abstract[55]|abstract[56]	giv[55]|giv[56]	coref	10-9[73_56]
7-31	1111-1120	annotated	abstract[55]|abstract[56]	giv[55]|giv[56]	_	_
7-32	1121-1126	genes	abstract[55]|abstract[56]	giv[55]|giv[56]	_	_
7-33	1127-1128	.	_	_	_	_

#Text=This has also been observed in a similar analysis of other human cancers .
8-1	1129-1133	This	abstract	giv	coref	9-9[66_0]
8-2	1134-1137	has	_	_	_	_
8-3	1138-1142	also	_	_	_	_
8-4	1143-1147	been	_	_	_	_
8-5	1148-1156	observed	_	_	_	_
8-6	1157-1159	in	_	_	_	_
8-7	1160-1161	a	abstract[58]	giv[58]	coref	27-4[252_58]
8-8	1162-1169	similar	abstract[58]	giv[58]	_	_
8-9	1170-1178	analysis	abstract[58]	giv[58]	_	_
8-10	1179-1181	of	abstract[58]	giv[58]	_	_
8-11	1182-1187	other	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-12	1188-1193	human	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-13	1194-1201	cancers	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
8-14	1202-1203	.	_	_	_	_

#Text=We observed a correlation between DNA methylation and gene expression in approximately 11 % of gene-associated CpGs with aberrant DNA methylation .
9-1	1204-1206	We	person	giv	ana	16-9
9-2	1207-1215	observed	_	_	_	_
9-3	1216-1217	a	abstract[61]	new[61]	coref	11-1[89_61]
9-4	1218-1229	correlation	abstract[61]	new[61]	_	_
9-5	1230-1237	between	abstract[61]	new[61]	_	_
9-6	1238-1241	DNA	abstract[61]|abstract|abstract[63]|abstract[64]	new[61]|giv|giv[63]|new[64]	coref|coref|coref	9-20|9-19[70_63]|10-12[76_64]
9-7	1242-1253	methylation	abstract[61]|abstract[63]|abstract[64]	new[61]|giv[63]|new[64]	_	_
9-8	1254-1257	and	abstract[61]|abstract[64]	new[61]|new[64]	_	_
9-9	1258-1262	gene	abstract[61]|abstract[64]|abstract|abstract[66]	new[61]|new[64]|giv|giv[66]	coref|coref	10-14[0_66]|13-9
9-10	1263-1273	expression	abstract[61]|abstract[64]|abstract[66]	new[61]|new[64]|giv[66]	_	_
9-11	1274-1276	in	_	_	_	_
9-12	1277-1290	approximately	abstract[67]	new[67]	_	_
9-13	1291-1293	11	abstract[67]	new[67]	_	_
9-14	1294-1295	%	abstract[67]	new[67]	_	_
9-15	1296-1298	of	abstract[67]	new[67]	_	_
9-16	1299-1314	gene-associated	abstract[67]|abstract[68]	new[67]|giv[68]	coref	12-14[104_68]
9-17	1315-1319	CpGs	abstract[67]|abstract[68]	new[67]|giv[68]	_	_
9-18	1320-1324	with	abstract[67]|abstract[68]	new[67]|giv[68]	_	_
9-19	1325-1333	aberrant	abstract[67]|abstract[68]|abstract[70]	new[67]|giv[68]|giv[70]	coref	10-12[0_70]
9-20	1334-1337	DNA	abstract[67]|abstract[68]|abstract|abstract[70]	new[67]|giv[68]|giv|giv[70]	coref	11-5
9-21	1338-1349	methylation	abstract[67]|abstract[68]|abstract[70]	new[67]|giv[68]|giv[70]	_	_
9-22	1350-1351	.	_	_	_	_

#Text=These CpG sites are located in or near genes for which methylation and expression were previously reported to be correlated in pituitary adenomas , including STAT5A , RHOD , GALNT9 , and RASSF1 , as well as genes with previously described aberrant methylation in pituitary tumors , including CDKN1A , TP73 , and STAT3 .
10-1	1352-1357	These	place[72]	new[72]	coref	13-20[115_72]
10-2	1358-1361	CpG	abstract|place[72]	giv|new[72]	_	_
10-3	1362-1367	sites	place[72]	new[72]	_	_
10-4	1368-1371	are	_	_	_	_
10-5	1372-1379	located	_	_	_	_
10-6	1380-1382	in	_	_	_	_
10-7	1383-1385	or	_	_	_	_
10-8	1386-1390	near	_	_	_	_
10-9	1391-1396	genes	abstract[73]|abstract[74]	giv[73]|giv[74]	coref|coref	10-9[74_73]|10-38[83_74]
10-10	1397-1400	for	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-11	1401-1406	which	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-12	1407-1418	methylation	abstract[73]|abstract[74]|abstract|abstract[76]	giv[73]|giv[74]|giv|giv[76]	coref|coref	10-40[84_0]|11-4[92_76]
10-13	1419-1422	and	abstract[73]|abstract[74]|abstract[76]	giv[73]|giv[74]|giv[76]	_	_
10-14	1423-1433	expression	abstract[73]|abstract[74]|abstract[76]|abstract	giv[73]|giv[74]|giv[76]|giv	coref	11-9
10-15	1434-1438	were	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-16	1439-1449	previously	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-17	1450-1458	reported	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-18	1459-1461	to	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-19	1462-1464	be	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-20	1465-1475	correlated	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-21	1476-1478	in	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-22	1479-1488	pituitary	abstract[73]|abstract[74]|animal[78]	giv[73]|giv[74]|giv[78]	_	_
10-23	1489-1497	adenomas	abstract[73]|abstract[74]|animal[78]	giv[73]|giv[74]|giv[78]	_	_
10-24	1498-1499	,	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-25	1500-1509	including	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-26	1510-1516	STAT5A	abstract[73]|abstract[74]|abstract	giv[73]|giv[74]|new	_	_
10-27	1517-1518	,	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-28	1519-1523	RHOD	abstract[73]|abstract[74]|abstract	giv[73]|giv[74]|new	_	_
10-29	1524-1525	,	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-30	1526-1532	GALNT9	abstract[73]|abstract[74]|abstract	giv[73]|giv[74]|new	_	_
10-31	1533-1534	,	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-32	1535-1538	and	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
10-33	1539-1545	RASSF1	abstract[73]|abstract[74]|abstract	giv[73]|giv[74]|new	_	_
10-34	1546-1547	,	abstract[74]	giv[74]	_	_
10-35	1548-1550	as	abstract[74]	giv[74]	_	_
10-36	1551-1555	well	abstract[74]	giv[74]	_	_
10-37	1556-1558	as	abstract[74]	giv[74]	_	_
10-38	1559-1564	genes	abstract[74]|abstract[83]	giv[74]|giv[83]	coref	12-4[100_83]
10-39	1565-1569	with	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-40	1570-1580	previously	abstract[74]|abstract[83]|abstract[84]	giv[74]|giv[83]|giv[84]	coref	11-4[91_84]
10-41	1581-1590	described	abstract[74]|abstract[83]|abstract[84]	giv[74]|giv[83]|giv[84]	_	_
10-42	1591-1599	aberrant	abstract[74]|abstract[83]|abstract[84]	giv[74]|giv[83]|giv[84]	_	_
10-43	1600-1611	methylation	abstract[74]|abstract[83]|abstract[84]	giv[74]|giv[83]|giv[84]	_	_
10-44	1612-1614	in	abstract[74]|abstract[83]|abstract[84]	giv[74]|giv[83]|giv[84]	_	_
10-45	1615-1624	pituitary	abstract[74]|abstract[83]|abstract[84]|object[85]	giv[74]|giv[83]|giv[84]|giv[85]	coref	11-26[98_85]
10-46	1625-1631	tumors	abstract[74]|abstract[83]|abstract[84]|object[85]	giv[74]|giv[83]|giv[84]|giv[85]	_	_
10-47	1632-1633	,	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-48	1634-1643	including	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-49	1644-1650	CDKN1A	abstract[74]|abstract[83]|abstract	giv[74]|giv[83]|new	_	_
10-50	1651-1652	,	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-51	1653-1657	TP73	abstract[74]|abstract[83]|abstract	giv[74]|giv[83]|new	_	_
10-52	1658-1659	,	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-53	1660-1663	and	abstract[74]|abstract[83]	giv[74]|giv[83]	_	_
10-54	1664-1669	STAT3	abstract[74]|abstract[83]|abstract	giv[74]|giv[83]|new	_	_
10-55	1670-1671	.	_	_	_	_

#Text=A correlation between aberrant DNA methylation and the expression level was also observed for HMGA2 , which plays an important role in the pathogenesis of pituitary tumors .
11-1	1672-1673	A	abstract[89]	giv[89]	coref	17-18[159_89]
11-2	1674-1685	correlation	abstract[89]	giv[89]	_	_
11-3	1686-1693	between	abstract[89]	giv[89]	_	_
11-4	1694-1702	aberrant	abstract[89]|abstract[91]|abstract[92]	giv[89]|giv[91]|giv[92]	coref|coref	12-11[0_91]|17-12[157_92]
11-5	1703-1706	DNA	abstract[89]|abstract|abstract[91]|abstract[92]	giv[89]|giv|giv[91]|giv[92]	coref	20-29
11-6	1707-1718	methylation	abstract[89]|abstract[91]|abstract[92]	giv[89]|giv[91]|giv[92]	_	_
11-7	1719-1722	and	abstract[89]|abstract[92]	giv[89]|giv[92]	_	_
11-8	1723-1726	the	abstract[89]|abstract[92]|abstract[94]	giv[89]|giv[92]|new[94]	coref	12-10[103_94]
11-9	1727-1737	expression	abstract[89]|abstract[92]|abstract|abstract[94]	giv[89]|giv[92]|giv|new[94]	coref	12-5[101_0]
11-10	1738-1743	level	abstract[89]|abstract[92]|abstract[94]	giv[89]|giv[92]|new[94]	_	_
11-11	1744-1747	was	_	_	_	_
11-12	1748-1752	also	_	_	_	_
11-13	1753-1761	observed	_	_	_	_
11-14	1762-1765	for	_	_	_	_
11-15	1766-1771	HMGA2	abstract[95]	new[95]	_	_
11-16	1772-1773	,	abstract[95]	new[95]	_	_
11-17	1774-1779	which	abstract[95]	new[95]	_	_
11-18	1780-1785	plays	abstract[95]	new[95]	_	_
11-19	1786-1788	an	abstract[95]|abstract[96]	new[95]|new[96]	_	_
11-20	1789-1798	important	abstract[95]|abstract[96]	new[95]|new[96]	_	_
11-21	1799-1803	role	abstract[95]|abstract[96]	new[95]|new[96]	_	_
11-22	1804-1806	in	abstract[95]|abstract[96]	new[95]|new[96]	_	_
11-23	1807-1810	the	abstract[95]|abstract[96]|abstract[97]	new[95]|new[96]|new[97]	_	_
11-24	1811-1823	pathogenesis	abstract[95]|abstract[96]|abstract[97]	new[95]|new[96]|new[97]	_	_
11-25	1824-1826	of	abstract[95]|abstract[96]|abstract[97]	new[95]|new[96]|new[97]	_	_
11-26	1827-1836	pituitary	abstract[95]|abstract[96]|abstract[97]|object[98]	new[95]|new[96]|new[97]|giv[98]	coref	14-12[0_98]
11-27	1837-1843	tumors	abstract[95]|abstract[96]|abstract[97]|object[98]	new[95]|new[96]|new[97]|giv[98]	_	_
11-28	1844-1845	.	_	_	_	_

#Text=GSEA revealed that genes whose expression was related to the methylation level of differentially methylated CpGs were enriched in pathways and processes important for tumor development .
12-1	1846-1850	GSEA	abstract	new	coref	25-6[236_0]
12-2	1851-1859	revealed	_	_	_	_
12-3	1860-1864	that	_	_	_	_
12-4	1865-1870	genes	abstract[100]	giv[100]	coref	14-28[129_100]
12-5	1871-1876	whose	abstract[100]|abstract[101]	giv[100]|giv[101]	coref	13-9[112_101]
12-6	1877-1887	expression	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
12-7	1888-1891	was	abstract[100]	giv[100]	_	_
12-8	1892-1899	related	abstract[100]	giv[100]	_	_
12-9	1900-1902	to	abstract[100]	giv[100]	_	_
12-10	1903-1906	the	abstract[100]|abstract[103]	giv[100]|giv[103]	_	_
12-11	1907-1918	methylation	abstract[100]|abstract|abstract[103]	giv[100]|giv|giv[103]	coref	13-4[110_0]
12-12	1919-1924	level	abstract[100]|abstract[103]	giv[100]|giv[103]	_	_
12-13	1925-1927	of	abstract[100]|abstract[103]	giv[100]|giv[103]	_	_
12-14	1928-1942	differentially	abstract[100]|abstract[103]|abstract[104]	giv[100]|giv[103]|giv[104]	coref	13-2[109_104]
12-15	1943-1953	methylated	abstract[100]|abstract[103]|abstract[104]	giv[100]|giv[103]|giv[104]	_	_
12-16	1954-1958	CpGs	abstract[100]|abstract[103]|abstract[104]	giv[100]|giv[103]|giv[104]	_	_
12-17	1959-1963	were	_	_	_	_
12-18	1964-1972	enriched	_	_	_	_
12-19	1973-1975	in	_	_	_	_
12-20	1976-1984	pathways	abstract	new	_	_
12-21	1985-1988	and	_	_	_	_
12-22	1989-1998	processes	abstract[106]	new[106]	_	_
12-23	1999-2008	important	abstract[106]	new[106]	_	_
12-24	2009-2012	for	_	_	_	_
12-25	2013-2018	tumor	object|event[108]	new|new[108]	_	_
12-26	2019-2030	development	event[108]	new[108]	_	_
12-27	2031-2032	.	_	_	_	_

#Text=For most CpGs whose methylation was related to gene expression , the relationship was an inverse one : For these sites , hypermethylation and hypomethylation corresponded to a decrease and increase in gene expression , respectively .
13-1	2033-2036	For	_	_	_	_
13-2	2037-2041	most	abstract[109]	giv[109]	coref	16-14[138_109]
13-3	2042-2046	CpGs	abstract[109]	giv[109]	_	_
13-4	2047-2052	whose	abstract[109]|abstract[110]	giv[109]|giv[110]	coref	14-14[125_110]
13-5	2053-2064	methylation	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
13-6	2065-2068	was	abstract[109]	giv[109]	_	_
13-7	2069-2076	related	abstract[109]	giv[109]	_	_
13-8	2077-2079	to	abstract[109]	giv[109]	_	_
13-9	2080-2084	gene	abstract[109]|abstract|abstract[112]	giv[109]|giv|giv[112]	coref|coref	13-33|13-33[121_112]
13-10	2085-2095	expression	abstract[109]|abstract[112]	giv[109]|giv[112]	_	_
13-11	2096-2097	,	_	_	_	_
13-12	2098-2101	the	abstract[113]	new[113]	_	_
13-13	2102-2114	relationship	abstract[113]	new[113]	_	_
13-14	2115-2118	was	_	_	_	_
13-15	2119-2121	an	abstract[114]	new[114]	_	_
13-16	2122-2129	inverse	abstract[114]	new[114]	_	_
13-17	2130-2133	one	abstract[114]	new[114]	_	_
13-18	2134-2135	:	_	_	_	_
13-19	2136-2139	For	_	_	_	_
13-20	2140-2145	these	place[115]	giv[115]	_	_
13-21	2146-2151	sites	place[115]	giv[115]	_	_
13-22	2152-2153	,	_	_	_	_
13-23	2154-2170	hypermethylation	abstract	new	coref	18-13
13-24	2171-2174	and	_	_	_	_
13-25	2175-2190	hypomethylation	abstract	new	coref	15-6
13-26	2191-2203	corresponded	_	_	_	_
13-27	2204-2206	to	_	_	_	_
13-28	2207-2208	a	event[118]	new[118]	_	_
13-29	2209-2217	decrease	event[118]	new[118]	_	_
13-30	2218-2221	and	_	_	_	_
13-31	2222-2230	increase	abstract[119]	giv[119]	_	_
13-32	2231-2233	in	abstract[119]	giv[119]	_	_
13-33	2234-2238	gene	abstract[119]|abstract|abstract[121]	giv[119]|giv|giv[121]	coref|coref	16-30|17-14[0_121]
13-34	2239-2249	expression	abstract[119]|abstract[121]	giv[119]|giv[121]	_	_
13-35	2250-2251	,	_	_	_	_
13-36	2252-2264	respectively	_	_	_	_
13-37	2265-2266	.	_	_	_	_

#Text=These results are generally in line with the idea that in tumors , elevated methylation is associated with transcriptional silencing , providing a mechanism for inactivation of genes with tumor-suppressor function .
14-1	2267-2272	These	abstract[122]	giv[122]	coref	16-6[135_122]
14-2	2273-2280	results	abstract[122]	giv[122]	_	_
14-3	2281-2284	are	_	_	_	_
14-4	2285-2294	generally	_	_	_	_
14-5	2295-2297	in	_	_	_	_
14-6	2298-2302	line	_	_	_	_
14-7	2303-2307	with	_	_	_	_
14-8	2308-2311	the	abstract[123]	new[123]	_	_
14-9	2312-2316	idea	abstract[123]	new[123]	_	_
14-10	2317-2321	that	abstract[123]	new[123]	_	_
14-11	2322-2324	in	abstract[123]	new[123]	_	_
14-12	2325-2331	tumors	abstract[123]|object	new[123]|giv	coref	23-49
14-13	2332-2333	,	abstract[123]	new[123]	_	_
14-14	2334-2342	elevated	abstract[123]|abstract[125]	new[123]|giv[125]	coref	17-12[0_125]
14-15	2343-2354	methylation	abstract[123]|abstract[125]	new[123]|giv[125]	_	_
14-16	2355-2357	is	abstract[123]	new[123]	_	_
14-17	2358-2368	associated	abstract[123]	new[123]	_	_
14-18	2369-2373	with	abstract[123]	new[123]	_	_
14-19	2374-2389	transcriptional	abstract[123]|abstract[126]	new[123]|new[126]	_	_
14-20	2390-2399	silencing	abstract[123]|abstract[126]	new[123]|new[126]	_	_
14-21	2400-2401	,	_	_	_	_
14-22	2402-2411	providing	_	_	_	_
14-23	2412-2413	a	abstract[127]	new[127]	coref	26-19[244_127]
14-24	2414-2423	mechanism	abstract[127]	new[127]	_	_
14-25	2424-2427	for	abstract[127]	new[127]	_	_
14-26	2428-2440	inactivation	abstract[127]|event[128]	new[127]|new[128]	_	_
14-27	2441-2443	of	abstract[127]|event[128]	new[127]|new[128]	_	_
14-28	2444-2449	genes	abstract[127]|event[128]|abstract[129]	new[127]|new[128]|giv[129]	coref	20-8[174_129]
14-29	2450-2454	with	abstract[127]|event[128]|abstract[129]	new[127]|new[128]|giv[129]	_	_
14-30	2455-2471	tumor-suppressor	abstract[127]|event[128]|abstract[129]|abstract[130]	new[127]|new[128]|giv[129]|new[130]	_	_
14-31	2472-2480	function	abstract[127]|event[128]|abstract[129]|abstract[130]	new[127]|new[128]|giv[129]|new[130]	_	_
14-32	2481-2482	.	_	_	_	_

#Text=On the other hand , hypomethylation may result in the activation of potential oncogenes .
15-1	2483-2485	On	_	_	_	_
15-2	2486-2489	the	_	_	_	_
15-3	2490-2495	other	_	_	_	_
15-4	2496-2500	hand	_	_	_	_
15-5	2501-2502	,	_	_	_	_
15-6	2503-2518	hypomethylation	abstract	giv	coref	18-15
15-7	2519-2522	may	_	_	_	_
15-8	2523-2529	result	_	_	_	_
15-9	2530-2532	in	_	_	_	_
15-10	2533-2536	the	event[132]	new[132]	_	_
15-11	2537-2547	activation	event[132]	new[132]	_	_
15-12	2548-2550	of	event[132]	new[132]	_	_
15-13	2551-2560	potential	event[132]|abstract[133]	new[132]|new[133]	_	_
15-14	2561-2570	oncogenes	event[132]|abstract[133]	new[132]|new[133]	_	_
15-15	2571-2572	.	_	_	_	_

#Text=To simplify the interpretation of the results , we distinguished two classes of aberrantly methylated CpGs : Those in promoters , i.e. , located in the 5 ’ promoter gene region , which includes regions from 1500 bp upstream of the TSS up to the first exon of the gene , and those in gene bodies , including exons , introns , and 3’UTR sequences .
16-1	2573-2575	To	_	_	_	_
16-2	2576-2584	simplify	_	_	_	_
16-3	2585-2588	the	abstract[134]	new[134]	_	_
16-4	2589-2603	interpretation	abstract[134]	new[134]	_	_
16-5	2604-2606	of	abstract[134]	new[134]	_	_
16-6	2607-2610	the	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
16-7	2611-2618	results	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
16-8	2619-2620	,	_	_	_	_
16-9	2621-2623	we	person	giv	ana	21-5
16-10	2624-2637	distinguished	_	_	_	_
16-11	2638-2641	two	abstract[137]	new[137]	_	_
16-12	2642-2649	classes	abstract[137]	new[137]	_	_
16-13	2650-2652	of	abstract[137]	new[137]	_	_
16-14	2653-2663	aberrantly	abstract[137]|abstract[138]	new[137]|giv[138]	coref	17-5[154_138]
16-15	2664-2674	methylated	abstract[137]|abstract[138]	new[137]|giv[138]	_	_
16-16	2675-2679	CpGs	abstract[137]|abstract[138]	new[137]|giv[138]	_	_
16-17	2680-2681	:	_	_	_	_
16-18	2682-2687	Those	_	_	_	_
16-19	2688-2690	in	_	_	_	_
16-20	2691-2700	promoters	person[139]	new[139]	coref	17-9[155_139]
16-21	2701-2702	,	person[139]	new[139]	_	_
16-22	2703-2707	i.e.	person[139]	new[139]	_	_
16-23	2708-2709	,	person[139]	new[139]	_	_
16-24	2710-2717	located	person[139]	new[139]	_	_
16-25	2718-2720	in	person[139]	new[139]	_	_
16-26	2721-2724	the	person[139]|place[142]	new[139]|new[142]	_	_
16-27	2725-2726	5	person[139]|place[142]	new[139]|new[142]	_	_
16-28	2727-2728	’	person[139]|place[142]	new[139]|new[142]	_	_
16-29	2729-2737	promoter	person[139]|person|place[142]	new[139]|new|new[142]	coref	20-23
16-30	2738-2742	gene	person[139]|abstract|place[142]	new[139]|giv|new[142]	coref	16-49[147_0]
16-31	2743-2749	region	person[139]|place[142]	new[139]|new[142]	_	_
16-32	2750-2751	,	person[139]|place[142]	new[139]|new[142]	_	_
16-33	2752-2757	which	person[139]|place[142]	new[139]|new[142]	_	_
16-34	2758-2766	includes	person[139]|place[142]	new[139]|new[142]	_	_
16-35	2767-2774	regions	person[139]|place[142]|place[143]	new[139]|new[142]|new[143]	_	_
16-36	2775-2779	from	person[139]|place[142]|place[143]	new[139]|new[142]|new[143]	_	_
16-37	2780-2784	1500	person[139]|place[142]|place[143]|abstract[144]	new[139]|new[142]|new[143]|new[144]	_	_
16-38	2785-2787	bp	person[139]|place[142]|place[143]|abstract[144]	new[139]|new[142]|new[143]|new[144]	_	_
16-39	2788-2796	upstream	person[139]|place[142]|place[143]|abstract[144]	new[139]|new[142]|new[143]|new[144]	_	_
16-40	2797-2799	of	_	_	_	_
16-41	2800-2803	the	abstract[145]	new[145]	_	_
16-42	2804-2807	TSS	abstract[145]	new[145]	_	_
16-43	2808-2810	up	_	_	_	_
16-44	2811-2813	to	_	_	_	_
16-45	2814-2817	the	abstract[146]	new[146]	_	_
16-46	2818-2823	first	abstract[146]	new[146]	_	_
16-47	2824-2828	exon	abstract[146]	new[146]	_	_
16-48	2829-2831	of	abstract[146]	new[146]	_	_
16-49	2832-2835	the	abstract[146]|abstract[147]	new[146]|giv[147]	coref	16-55[0_147]
16-50	2836-2840	gene	abstract[146]|abstract[147]	new[146]|giv[147]	_	_
16-51	2841-2842	,	_	_	_	_
16-52	2843-2846	and	_	_	_	_
16-53	2847-2852	those	_	_	_	_
16-54	2853-2855	in	_	_	_	_
16-55	2856-2860	gene	abstract|object[149]	giv|new[149]	coref|coref	19-9|19-9[168_149]
16-56	2861-2867	bodies	object[149]	new[149]	_	_
16-57	2868-2869	,	_	_	_	_
16-58	2870-2879	including	_	_	_	_
16-59	2880-2885	exons	abstract	new	_	_
16-60	2886-2887	,	_	_	_	_
16-61	2888-2895	introns	abstract	new	_	_
16-62	2896-2897	,	_	_	_	_
16-63	2898-2901	and	_	_	_	_
16-64	2902-2907	3’UTR	abstract[152]	new[152]	_	_
16-65	2908-2917	sequences	abstract[152]	new[152]	_	_
16-66	2918-2919	.	_	_	_	_

#Text=For 81 % of the CpGs located in promoters for which methylation and expression were correlated , the correlation was negative , in concordance with the overall model .
17-1	2920-2923	For	_	_	_	_
17-2	2924-2926	81	abstract[153]	new[153]	_	_
17-3	2927-2928	%	abstract[153]	new[153]	_	_
17-4	2929-2931	of	abstract[153]	new[153]	_	_
17-5	2932-2935	the	abstract[153]|abstract[154]	new[153]|giv[154]	coref	18-4[162_154]
17-6	2936-2940	CpGs	abstract[153]|abstract[154]	new[153]|giv[154]	_	_
17-7	2941-2948	located	abstract[153]|abstract[154]	new[153]|giv[154]	_	_
17-8	2949-2951	in	abstract[153]|abstract[154]	new[153]|giv[154]	_	_
17-9	2952-2961	promoters	abstract[153]|abstract[154]|person[155]	new[153]|giv[154]|giv[155]	coref	19-19[0_155]
17-10	2962-2965	for	abstract[153]|abstract[154]|person[155]	new[153]|giv[154]|giv[155]	_	_
17-11	2966-2971	which	abstract[153]|abstract[154]|person[155]	new[153]|giv[154]|giv[155]	_	_
17-12	2972-2983	methylation	abstract[153]|abstract[154]|person[155]|abstract|abstract[157]	new[153]|giv[154]|giv[155]|giv|giv[157]	coref	20-1[173_0]
17-13	2984-2987	and	abstract[153]|abstract[154]|person[155]|abstract[157]	new[153]|giv[154]|giv[155]|giv[157]	_	_
17-14	2988-2998	expression	abstract[153]|abstract[154]|person[155]|abstract[157]|abstract	new[153]|giv[154]|giv[155]|giv[157]|giv	coref	18-19[165_0]
17-15	2999-3003	were	abstract[153]|abstract[154]|person[155]	new[153]|giv[154]|giv[155]	_	_
17-16	3004-3014	correlated	abstract[153]|abstract[154]|person[155]	new[153]|giv[154]|giv[155]	_	_
17-17	3015-3016	,	_	_	_	_
17-18	3017-3020	the	abstract[159]	giv[159]	coref	23-9[208_159]
17-19	3021-3032	correlation	abstract[159]	giv[159]	_	_
17-20	3033-3036	was	_	_	_	_
17-21	3037-3045	negative	_	_	_	_
17-22	3046-3047	,	_	_	_	_
17-23	3048-3050	in	_	_	_	_
17-24	3051-3062	concordance	abstract[160]	new[160]	_	_
17-25	3063-3067	with	abstract[160]	new[160]	_	_
17-26	3068-3071	the	abstract[160]|abstract[161]	new[160]|new[161]	_	_
17-27	3072-3079	overall	abstract[160]|abstract[161]	new[160]|new[161]	_	_
17-28	3080-3085	model	abstract[160]|abstract[161]	new[160]|new[161]	_	_
17-29	3086-3087	.	_	_	_	_

#Text=Approximately one-third of all methylation/expression-correlated CpGs were positively correlated , i.e. , hypermethylation and hypomethylation were associated with increased and decreased expression , respectively .
18-1	3088-3101	Approximately	_	_	_	_
18-2	3102-3111	one-third	_	_	_	_
18-3	3112-3114	of	_	_	_	_
18-4	3115-3118	all	abstract[162]	giv[162]	coref	19-2[166_162]
18-5	3119-3152	methylation/expression-correlated	abstract[162]	giv[162]	_	_
18-6	3153-3157	CpGs	abstract[162]	giv[162]	_	_
18-7	3158-3162	were	_	_	_	_
18-8	3163-3173	positively	_	_	_	_
18-9	3174-3184	correlated	_	_	_	_
18-10	3185-3186	,	_	_	_	_
18-11	3187-3191	i.e.	_	_	_	_
18-12	3192-3193	,	_	_	_	_
18-13	3194-3210	hypermethylation	abstract	giv	_	_
18-14	3211-3214	and	_	_	_	_
18-15	3215-3230	hypomethylation	abstract	giv	_	_
18-16	3231-3235	were	_	_	_	_
18-17	3236-3246	associated	_	_	_	_
18-18	3247-3251	with	_	_	_	_
18-19	3252-3261	increased	abstract[165]	giv[165]	coref	20-20[178_165]
18-20	3262-3265	and	abstract[165]	giv[165]	_	_
18-21	3266-3275	decreased	abstract[165]	giv[165]	_	_
18-22	3276-3286	expression	abstract[165]	giv[165]	_	_
18-23	3287-3288	,	_	_	_	_
18-24	3289-3301	respectively	_	_	_	_
18-25	3302-3303	.	_	_	_	_

#Text=Among these CpGs , most are located in gene bodies , whereas only 22 % are located in promoters , consistent with previously published reports .
19-1	3304-3309	Among	_	_	_	_
19-2	3310-3315	these	abstract[166]	giv[166]	_	_
19-3	3316-3320	CpGs	abstract[166]	giv[166]	_	_
19-4	3321-3322	,	_	_	_	_
19-5	3323-3327	most	_	_	_	_
19-6	3328-3331	are	_	_	_	_
19-7	3332-3339	located	_	_	_	_
19-8	3340-3342	in	_	_	_	_
19-9	3343-3347	gene	abstract|object[168]	giv|giv[168]	coref|coref	20-20|20-32[184_168]
19-10	3348-3354	bodies	object[168]	giv[168]	_	_
19-11	3355-3356	,	_	_	_	_
19-12	3357-3364	whereas	_	_	_	_
19-13	3365-3369	only	abstract[169]	new[169]	_	_
19-14	3370-3372	22	abstract[169]	new[169]	_	_
19-15	3373-3374	%	abstract[169]	new[169]	_	_
19-16	3375-3378	are	_	_	_	_
19-17	3379-3386	located	_	_	_	_
19-18	3387-3389	in	_	_	_	_
19-19	3390-3399	promoters	person	giv	_	_
19-20	3400-3401	,	_	_	_	_
19-21	3402-3412	consistent	_	_	_	_
19-22	3413-3417	with	_	_	_	_
19-23	3418-3428	previously	abstract[171]	new[171]	_	_
19-24	3429-3438	published	abstract[171]	new[171]	_	_
19-25	3439-3446	reports	abstract[171]	new[171]	_	_
19-26	3447-3448	.	_	_	_	_

#Text=Gene body methylation has been observed in active genes , implying that it may have the opposite effect on gene expression to promoter methylation , i.e. , increased DNA methylation in gene bodies may promote transcription .
20-1	3449-3453	Gene	object[172]|abstract[173]	new[172]|giv[173]	ana	20-13[0_173]
20-2	3454-3458	body	object[172]|abstract[173]	new[172]|giv[173]	_	_
20-3	3459-3470	methylation	abstract[173]	giv[173]	_	_
20-4	3471-3474	has	_	_	_	_
20-5	3475-3479	been	_	_	_	_
20-6	3480-3488	observed	_	_	_	_
20-7	3489-3491	in	_	_	_	_
20-8	3492-3498	active	abstract[174]	giv[174]	coref	22-11[202_174]
20-9	3499-3504	genes	abstract[174]	giv[174]	_	_
20-10	3505-3506	,	_	_	_	_
20-11	3507-3515	implying	_	_	_	_
20-12	3516-3520	that	_	_	_	_
20-13	3521-3523	it	abstract	giv	coref	20-23[180_0]
20-14	3524-3527	may	_	_	_	_
20-15	3528-3532	have	_	_	_	_
20-16	3533-3536	the	abstract[176]	new[176]	_	_
20-17	3537-3545	opposite	abstract[176]	new[176]	_	_
20-18	3546-3552	effect	abstract[176]	new[176]	_	_
20-19	3553-3555	on	abstract[176]	new[176]	_	_
20-20	3556-3560	gene	abstract[176]|abstract|abstract[178]	new[176]|giv|giv[178]	coref|coref	20-32|21-8[0_178]
20-21	3561-3571	expression	abstract[176]|abstract[178]	new[176]|giv[178]	_	_
20-22	3572-3574	to	_	_	_	_
20-23	3575-3583	promoter	person|abstract[180]	giv|giv[180]	coref	20-28[182_180]
20-24	3584-3595	methylation	abstract[180]	giv[180]	_	_
20-25	3596-3597	,	_	_	_	_
20-26	3598-3602	i.e.	_	_	_	_
20-27	3603-3604	,	_	_	_	_
20-28	3605-3614	increased	abstract[182]	giv[182]	coref	24-20[228_182]
20-29	3615-3618	DNA	abstract|abstract[182]	giv|giv[182]	coref	24-20
20-30	3619-3630	methylation	abstract[182]	giv[182]	_	_
20-31	3631-3633	in	abstract[182]	giv[182]	_	_
20-32	3634-3638	gene	abstract[182]|abstract|object[184]	giv[182]|giv|giv[184]	_	_
20-33	3639-3645	bodies	abstract[182]|object[184]	giv[182]|giv[184]	_	_
20-34	3646-3649	may	_	_	_	_
20-35	3650-3657	promote	_	_	_	_
20-36	3658-3671	transcription	abstract	new	_	_
20-37	3672-3673	.	_	_	_	_

#Text=In this study , we compared the expression profiles of NFPAs and normal pituitary sections without evidence of neoplastic features , obtained by Rathke ’s cleft cyst surgery .
21-1	3674-3676	In	_	_	_	_
21-2	3677-3681	this	abstract[186]	giv[186]	_	_
21-3	3682-3687	study	abstract[186]	giv[186]	_	_
21-4	3688-3689	,	_	_	_	_
21-5	3690-3692	we	person	giv	ana	22-3
21-6	3693-3701	compared	_	_	_	_
21-7	3702-3705	the	abstract[189]	new[189]	_	_
21-8	3706-3716	expression	abstract|abstract[189]	giv|new[189]	coref	22-14[203_0]
21-9	3717-3725	profiles	abstract[189]	new[189]	_	_
21-10	3726-3728	of	abstract[189]	new[189]	_	_
21-11	3729-3734	NFPAs	abstract[189]|abstract|abstract[191]	new[189]|giv|giv[191]	coref|coref	21-11[191_0]|26-12[0_191]
21-12	3735-3738	and	abstract[189]|abstract[191]	new[189]|giv[191]	_	_
21-13	3739-3745	normal	abstract[189]|abstract[191]|object[193]	new[189]|giv[191]|giv[193]	_	_
21-14	3746-3755	pituitary	abstract[189]|abstract[191]|person|object[193]	new[189]|giv[191]|new|giv[193]	_	_
21-15	3756-3764	sections	abstract[189]|abstract[191]|object[193]	new[189]|giv[191]|giv[193]	_	_
21-16	3765-3772	without	abstract[189]|abstract[191]|object[193]	new[189]|giv[191]|giv[193]	_	_
21-17	3773-3781	evidence	abstract[189]|abstract[191]|object[193]|abstract[194]	new[189]|giv[191]|giv[193]|new[194]	_	_
21-18	3782-3784	of	abstract[189]|abstract[191]|object[193]|abstract[194]	new[189]|giv[191]|giv[193]|new[194]	_	_
21-19	3785-3795	neoplastic	abstract[189]|abstract[191]|object[193]|abstract[194]|abstract[195]	new[189]|giv[191]|giv[193]|new[194]|new[195]	_	_
21-20	3796-3804	features	abstract[189]|abstract[191]|object[193]|abstract[194]|abstract[195]	new[189]|giv[191]|giv[193]|new[194]|new[195]	_	_
21-21	3805-3806	,	_	_	_	_
21-22	3807-3815	obtained	_	_	_	_
21-23	3816-3818	by	_	_	_	_
21-24	3819-3825	Rathke	person[196]|event[198]	new[196]|new[198]	ana	22-1[0_198]
21-25	3826-3828	’s	person[196]|event[198]	new[196]|new[198]	_	_
21-26	3829-3834	cleft	object[197]|event[198]	new[197]|new[198]	_	_
21-27	3835-3839	cyst	object[197]|event[198]	new[197]|new[198]	_	_
21-28	3840-3847	surgery	event[198]	new[198]	_	_
21-29	3848-3849	.	_	_	_	_

#Text=This allowed us to identify DEGs and investigate which of these genes exhibits methylation-dependent expression .
22-1	3850-3854	This	event	giv	_	_
22-2	3855-3862	allowed	_	_	_	_
22-3	3863-3865	us	person	giv	ana	23-2
22-4	3866-3868	to	_	_	_	_
22-5	3869-3877	identify	_	_	_	_
22-6	3878-3882	DEGs	abstract	new	coref	23-15
22-7	3883-3886	and	_	_	_	_
22-8	3887-3898	investigate	_	_	_	_
22-9	3899-3904	which	_	_	_	_
22-10	3905-3907	of	_	_	_	_
22-11	3908-3913	these	abstract[202]	giv[202]	coref	23-7[206_202]
22-12	3914-3919	genes	abstract[202]	giv[202]	_	_
22-13	3920-3928	exhibits	_	_	_	_
22-14	3929-3950	methylation-dependent	abstract[203]	giv[203]	coref	23-26[0_203]
22-15	3951-3961	expression	abstract[203]	giv[203]	_	_
22-16	3962-3963	.	_	_	_	_

#Text=When we compared the list of genes with methylation/expression correlation and the list of DEGs , most genes were hypermethylated with a fold change in expression corresponding to the sign of the correlation , e.g. , a gene with negative methylation/expression correlation that was hypermethylated and downregulated in tumors .
23-1	3964-3968	When	_	_	_	_
23-2	3969-3971	we	person	giv	ana	26-1
23-3	3972-3980	compared	_	_	_	_
23-4	3981-3984	the	abstract[205]	new[205]	_	_
23-5	3985-3989	list	abstract[205]	new[205]	_	_
23-6	3990-3992	of	abstract[205]	new[205]	_	_
23-7	3993-3998	genes	abstract[205]|abstract[206]	new[205]|giv[206]	coref	23-17[211_206]
23-8	3999-4003	with	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
23-9	4004-4026	methylation/expression	abstract[205]|abstract[206]|abstract|abstract[208]	new[205]|giv[206]|new|giv[208]	coref|coref	23-32[216_208]|23-41
23-10	4027-4038	correlation	abstract[205]|abstract[206]|abstract[208]	new[205]|giv[206]|giv[208]	_	_
23-11	4039-4042	and	_	_	_	_
23-12	4043-4046	the	abstract[209]	new[209]	_	_
23-13	4047-4051	list	abstract[209]	new[209]	_	_
23-14	4052-4054	of	abstract[209]	new[209]	_	_
23-15	4055-4059	DEGs	abstract[209]|abstract	new[209]|giv	coref	27-18
23-16	4060-4061	,	_	_	_	_
23-17	4062-4066	most	abstract[211]	giv[211]	coref	24-5[0_211]
23-18	4067-4072	genes	abstract[211]	giv[211]	_	_
23-19	4073-4077	were	_	_	_	_
23-20	4078-4093	hypermethylated	_	_	_	_
23-21	4094-4098	with	_	_	_	_
23-22	4099-4100	a	abstract[213]	new[213]	appos	23-35[217_213]
23-23	4101-4105	fold	abstract|abstract[213]	new|new[213]	coref	24-10
23-24	4106-4112	change	abstract[213]	new[213]	_	_
23-25	4113-4115	in	abstract[213]	new[213]	_	_
23-26	4116-4126	expression	abstract[213]|abstract	new[213]|giv	coref	24-13
23-27	4127-4140	corresponding	abstract[213]	new[213]	_	_
23-28	4141-4143	to	abstract[213]	new[213]	_	_
23-29	4144-4147	the	abstract[213]|abstract[215]	new[213]|new[215]	coref	24-23[229_215]
23-30	4148-4152	sign	abstract[213]|abstract[215]	new[213]|new[215]	_	_
23-31	4153-4155	of	abstract[213]|abstract[215]	new[213]|new[215]	_	_
23-32	4156-4159	the	abstract[213]|abstract[215]|abstract[216]	new[213]|new[215]|giv[216]	coref	23-40[219_216]
23-33	4160-4171	correlation	abstract[213]|abstract[215]|abstract[216]	new[213]|new[215]|giv[216]	_	_
23-34	4172-4173	,	_	_	_	_
23-35	4174-4178	e.g.	abstract[217]	giv[217]	coref	24-9[224_217]
23-36	4179-4180	,	abstract[217]	giv[217]	_	_
23-37	4181-4182	a	abstract[217]	giv[217]	_	_
23-38	4183-4187	gene	abstract[217]	giv[217]	_	_
23-39	4188-4192	with	abstract[217]	giv[217]	_	_
23-40	4193-4201	negative	abstract[217]|abstract[219]	giv[217]|giv[219]	coref	24-26[230_219]
23-41	4202-4224	methylation/expression	abstract[217]|abstract|abstract[219]	giv[217]|giv|giv[219]	coref	24-36
23-42	4225-4236	correlation	abstract[217]|abstract[219]	giv[217]|giv[219]	_	_
23-43	4237-4241	that	abstract[217]	giv[217]	_	_
23-44	4242-4245	was	abstract[217]	giv[217]	_	_
23-45	4246-4261	hypermethylated	abstract[217]	giv[217]	_	_
23-46	4262-4265	and	abstract[217]	giv[217]	_	_
23-47	4266-4279	downregulated	abstract[217]	giv[217]	_	_
23-48	4280-4282	in	_	_	_	_
23-49	4283-4289	tumors	object	giv	coref	24-42
23-50	4290-4291	.	_	_	_	_

#Text=In a subset of genes , however , the fold change in expression was inconsistent with the difference in DNA methylation and the sign of the correlation , e.g. , a hypermethylated gene with negative methylation/expression correlation that was upregulated in tumors .
24-1	4292-4294	In	_	_	_	_
24-2	4295-4296	a	abstract[221]	new[221]	_	_
24-3	4297-4303	subset	abstract[221]	new[221]	_	_
24-4	4304-4306	of	abstract[221]	new[221]	_	_
24-5	4307-4312	genes	abstract[221]|abstract	new[221]|giv	coref	25-1[235_0]
24-6	4313-4314	,	_	_	_	_
24-7	4315-4322	however	_	_	_	_
24-8	4323-4324	,	_	_	_	_
24-9	4325-4328	the	abstract[224]	giv[224]	coref	24-29[231_224]
24-10	4329-4333	fold	abstract|abstract[224]	giv|giv[224]	_	_
24-11	4334-4340	change	abstract[224]	giv[224]	_	_
24-12	4341-4343	in	abstract[224]	giv[224]	_	_
24-13	4344-4354	expression	abstract[224]|abstract	giv[224]|giv	_	_
24-14	4355-4358	was	_	_	_	_
24-15	4359-4371	inconsistent	_	_	_	_
24-16	4372-4376	with	_	_	_	_
24-17	4377-4380	the	abstract[226]	new[226]	_	_
24-18	4381-4391	difference	abstract[226]	new[226]	_	_
24-19	4392-4394	in	abstract[226]	new[226]	_	_
24-20	4395-4398	DNA	abstract[226]|abstract|abstract[228]	new[226]|giv|giv[228]	coref|coref	26-24|26-23[246_228]
24-21	4399-4410	methylation	abstract[226]|abstract[228]	new[226]|giv[228]	_	_
24-22	4411-4414	and	_	_	_	_
24-23	4415-4418	the	abstract[229]	giv[229]	_	_
24-24	4419-4423	sign	abstract[229]	giv[229]	_	_
24-25	4424-4426	of	abstract[229]	giv[229]	_	_
24-26	4427-4430	the	abstract[229]|abstract[230]	giv[229]|giv[230]	coref	24-35[233_230]
24-27	4431-4442	correlation	abstract[229]|abstract[230]	giv[229]|giv[230]	_	_
24-28	4443-4444	,	_	_	_	_
24-29	4445-4449	e.g.	abstract[231]	giv[231]	_	_
24-30	4450-4451	,	abstract[231]	giv[231]	_	_
24-31	4452-4453	a	abstract[231]	giv[231]	_	_
24-32	4454-4469	hypermethylated	abstract[231]	giv[231]	_	_
24-33	4470-4474	gene	abstract[231]	giv[231]	_	_
24-34	4475-4479	with	abstract[231]	giv[231]	_	_
24-35	4480-4488	negative	abstract[231]|abstract[233]	giv[231]|giv[233]	_	_
24-36	4489-4511	methylation/expression	abstract[231]|abstract|abstract[233]	giv[231]|giv|giv[233]	_	_
24-37	4512-4523	correlation	abstract[231]|abstract[233]	giv[231]|giv[233]	_	_
24-38	4524-4528	that	abstract[231]	giv[231]	_	_
24-39	4529-4532	was	abstract[231]	giv[231]	_	_
24-40	4533-4544	upregulated	abstract[231]	giv[231]	_	_
24-41	4545-4547	in	abstract[231]	giv[231]	_	_
24-42	4548-4554	tumors	abstract[231]|object	giv[231]|giv	_	_
24-43	4555-4556	.	_	_	_	_

#Text=These genes were excluded from the functional GSEA .
25-1	4557-4562	These	abstract[235]	giv[235]	coref	26-9[240_235]
25-2	4563-4568	genes	abstract[235]	giv[235]	_	_
25-3	4569-4573	were	_	_	_	_
25-4	4574-4582	excluded	_	_	_	_
25-5	4583-4587	from	_	_	_	_
25-6	4588-4591	the	abstract[236]	giv[236]	_	_
25-7	4592-4602	functional	abstract[236]	giv[236]	_	_
25-8	4603-4607	GSEA	abstract[236]	giv[236]	_	_
25-9	4608-4609	.	_	_	_	_

#Text=We believe that the differential the expression of these genes in NFPAs and pituitary tissue was due to a mechanism distinct from aberrant DNA methylation , despite the fact that the expression levels of these genes were methylation-related .
26-1	4610-4612	We	person	giv	ana	27-4
26-2	4613-4620	believe	_	_	_	_
26-3	4621-4625	that	_	_	_	_
26-4	4626-4629	the	abstract[239]	new[239]	coref	26-32[0_239]
26-5	4630-4642	differential	abstract|abstract[239]	new|new[239]	_	_
26-6	4643-4646	the	abstract[239]	new[239]	_	_
26-7	4647-4657	expression	abstract[239]	new[239]	_	_
26-8	4658-4660	of	abstract[239]	new[239]	_	_
26-9	4661-4666	these	abstract[239]|abstract[240]	new[239]|giv[240]	coref	26-35[250_240]
26-10	4667-4672	genes	abstract[239]|abstract[240]	new[239]|giv[240]	_	_
26-11	4673-4675	in	abstract[239]	new[239]	_	_
26-12	4676-4681	NFPAs	abstract[239]|abstract|abstract[242]	new[239]|giv|giv[242]	coref|coref	26-12[242_0]|27-9[254_242]
26-13	4682-4685	and	abstract[239]|abstract[242]	new[239]|giv[242]	_	_
26-14	4686-4695	pituitary	abstract[239]|abstract[242]|object[243]	new[239]|giv[242]|new[243]	_	_
26-15	4696-4702	tissue	abstract[239]|abstract[242]|object[243]	new[239]|giv[242]|new[243]	_	_
26-16	4703-4706	was	_	_	_	_
26-17	4707-4710	due	_	_	_	_
26-18	4711-4713	to	_	_	_	_
26-19	4714-4715	a	abstract[244]	giv[244]	_	_
26-20	4716-4725	mechanism	abstract[244]	giv[244]	_	_
26-21	4726-4734	distinct	abstract[244]	giv[244]	_	_
26-22	4735-4739	from	_	_	_	_
26-23	4740-4748	aberrant	abstract[246]	giv[246]	coref	27-22[258_246]
26-24	4749-4752	DNA	abstract|abstract[246]	giv|giv[246]	_	_
26-25	4753-4764	methylation	abstract[246]	giv[246]	_	_
26-26	4765-4766	,	_	_	_	_
26-27	4767-4774	despite	_	_	_	_
26-28	4775-4778	the	abstract[247]	new[247]	_	_
26-29	4779-4783	fact	abstract[247]	new[247]	_	_
26-30	4784-4788	that	abstract[247]	new[247]	_	_
26-31	4789-4792	the	abstract[247]|abstract[249]	new[247]|new[249]	_	_
26-32	4793-4803	expression	abstract[247]|abstract|abstract[249]	new[247]|giv|new[249]	_	_
26-33	4804-4810	levels	abstract[247]|abstract[249]	new[247]|new[249]	_	_
26-34	4811-4813	of	abstract[247]|abstract[249]	new[247]|new[249]	_	_
26-35	4814-4819	these	abstract[247]|abstract[249]|abstract[250]	new[247]|new[249]|giv[250]	_	_
26-36	4820-4825	genes	abstract[247]|abstract[249]|abstract[250]	new[247]|new[249]|giv[250]	_	_
26-37	4826-4830	were	abstract[247]	new[247]	_	_
26-38	4831-4850	methylation-related	abstract[247]	new[247]	_	_
26-39	4851-4852	.	_	_	_	_

#Text=In general , our analysis showed that in gonadotroph NFPAs , the expression of 9 % of DEGs is correlated with aberrant methylation .
27-1	4853-4855	In	_	_	_	_
27-2	4856-4863	general	_	_	_	_
27-3	4864-4865	,	_	_	_	_
27-4	4866-4869	our	person|abstract[252]	giv|giv[252]	_	_
27-5	4870-4878	analysis	abstract[252]	giv[252]	_	_
27-6	4879-4885	showed	_	_	_	_
27-7	4886-4890	that	_	_	_	_
27-8	4891-4893	in	_	_	_	_
27-9	4894-4905	gonadotroph	animal|abstract[254]	giv|giv[254]	_	_
27-10	4906-4911	NFPAs	abstract[254]	giv[254]	_	_
27-11	4912-4913	,	_	_	_	_
27-12	4914-4917	the	abstract[255]	new[255]	_	_
27-13	4918-4928	expression	abstract[255]	new[255]	_	_
27-14	4929-4931	of	abstract[255]	new[255]	_	_
27-15	4932-4933	9	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-16	4934-4935	%	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-17	4936-4938	of	abstract[255]|abstract[256]	new[255]|new[256]	_	_
27-18	4939-4943	DEGs	abstract[255]|abstract[256]|abstract	new[255]|new[256]|giv	_	_
27-19	4944-4946	is	_	_	_	_
27-20	4947-4957	correlated	_	_	_	_
27-21	4958-4962	with	_	_	_	_
27-22	4963-4971	aberrant	abstract[258]	giv[258]	_	_
27-23	4972-4983	methylation	abstract[258]	giv[258]	_	_
27-24	4984-4985	.	_	_	_	_
